![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 50, 35331-35336, December 10, 1999
§¶,
,
, and

From
AgResearch, Ruakura Research Centre,
Private Bag 3123, Hamilton, New Zealand, the
Division of Cell
and Molecular Biology, Department of Biology, Boston University,
Boston, Massachusetts 02215, and the ** Department of Anatomy and
Structural Biology, School of Medical Sciences, University of Otago,
Dunedin, New Zealand
| |
ABSTRACT |
|---|
|
|
|---|
The signal transducer and transcriptional
activator STAT5b is required to maintain the adult male pattern of
liver gene expression and whole body pubertal growth rates, as
demonstrated by the loss of these growth hormone (GH)
pulse-dependent responses in mice with a targeted
disruption of the STAT5b gene. The present study investigates whether these phenotypes of STAT5b-deficient mice result
from impaired intracellular GH signaling associated with a loss of GH
pulse responsiveness, as contrasted with a feminization of the
pituitary GH secretory profile leading to the observed feminization of
body growth and liver gene expression. Pulsatile GH replacement in
hypophysectomized mice stimulated body weight gain in wild-type but not
in STAT5b-deficient mice. Expression of the male-specific liver P450
enzyme CYP2D9, which is reduced to female levels in hypophysectomized
male mice, was restored to male levels by GH pulse replacement in
wild-type but not in STAT5b-deficient mice. Similarly, a
female-specific liver CYP2B P450 enzyme that was up-regulated to female
levels following hypophysectomy of males was suppressed to normal basal
male levels by GH pulses only in wild-type hypophysectomized mice.
Finally, urinary excretion of the male-specific, GH pulse-induced major
urinary protein was restored to normal male levels following pulsatile
GH treatment only in the case of wild-type hypophysectomized mice.
STAT5b-deficient mice are thus GH pulse-resistant, supporting the
proposed role of STAT5b as a key intracellular mediator of the
stimulatory effects of plasma GH pulses on the male pattern of liver
gene expression.
Growth hormone (GH)1 has
diverse effects on metabolism and growth that can result from the
direct effects of GH on gene expression, or may be indirectly mediated
by factors such as insulin-like growth factor I (1). In addition, the
temporal patterns of pituitary GH secretion differ in males and females
in many species, resulting in the expression of some genes
predominantly in males and other genes predominantly in females (2-4).
In male rats, plasma GH pulses are separated by periods of >2 h during
which there is negligible GH detectable in blood. In contrast, the
female plasma GH pattern is characterized by a more continuous presence of GH or, in some species such as mice, by more frequent pulses of GH
(3, 5).
GH binds to cell surface receptors that dimerize upon hormone binding
and subsequently activate the receptor-associated tyrosine kinase JAK2.
JAK2 in turn phosphorylates itself and the GH receptor on multiple
tyrosine residues. STAT proteins are then recruited to the GH
receptor/JAK2 complex and are phosphorylated on tyrosine and
subsequently on serine. STAT proteins activated in this manner form
homo- or heterodimers and translocate to the nucleus where they bind to
target sites in GH-responsive genes (6, 7). STAT5 proteins in the liver
are intermittently, and repeatedly, activated in response to GH pulses
(8, 9). GH also activates liver STAT1 and STAT3, but the activation of
these STATs is largely independent of the temporal pattern of GH in
blood (10).
STAT5a and STAT5b are encoded by different genes; however, they share
>90% amino acid identity. While initially referred to as mammary
gland factor because of the role in mediating the effects of prolactin
on the expression of The involvement of STAT5b in GH-pulse responsive liver gene expression
was recognized from studies in which liver STAT5b tyrosine phosphorylation, nuclear localization, and DNA binding were temporally correlated with plasma GH pulses and with the pattern of male-specific liver gene expression (8). Further confirmation came from the finding
that certain GH pulse-regulated, male-specific liver P450 genes contain
STAT5 response elements (21), from the recent demonstration that STAT5b
nuclear localization correlates with the gender-specific expression of
P450 genes in wild-type and estrogen receptor- In the present study, we address this question by directly examining
the effects of exogenous GH pulses given to mice where the major source
of endogenous GH has been eliminated by hypophysectomy. The effects of
pulsatile GH replacement on body weight gain and on the gender-specific
expression of genes in the liver were analyzed. Pulsatile GH
replacement in wild-type but not STAT5b-deficient mice is shown to
restore expression of genes normally expressed in intact male mice.
Additionally, GH pulse replacement is shown to increase overall body
weight gain in wild-type but not in STAT5b-deficient mice. These data
strongly support our proposal that the STAT5b pathway directly mediates
physiological signaling in hepatocytes in response to pulsatile GH stimulation.
Animals--
Male outcrossed 129 × BALB/c wild-type and
STAT5b gene-disrupted mice (23) were hypophysectomized at 4-17 weeks
of age and maintained on a 12-h light, 12-h dark schedule with free
access to food and drinking water supplemented with 5% glucose. After a recovery period of at least 7.5 weeks, the mice were given pulsatile GH replacement by injection. GH (2 µg/g body weight) was injected intraperitoneally at 12-h intervals for 7 days, either alone or combined with T4 (0.2 µg/ml added to the 5%
glucose/drinking water to give an approximate dose of 20 ng of
T4/g of body weight/day). This hormone replacement regimen
has been shown to re-establish male-specific patterns of liver P450
gene expression in GH-deficient mice (24). Administration of
T4 in combination with GH is required for expression of MUP
proteins (25). Urine was collected and body weights were monitored
during the hormone replacement period. The mice were maintained without
hormone treatment for another 3-6 weeks, at which time they were
killed to collect untreated hypophysectomized livers, or were given GH
pulse replacement without T4 as described above. Mice were
killed by CO2 asphyxiation, and the tissues were
snap-frozen in liquid nitrogen and stored at Hypophysectomy--
Mice were anesthetized using a mixture of
ketamine and rompun (intraperitoneal injection of 120 µg of ketamine
hydrochloride (Bristol-Meyers Co.) and 12 µg of xylozine
hydrochloride (Rompun, Bayer NZ Ltd., Auckland, NZ) per g of body
weight) and hypophysectomized by the parapharyngeal route (26).
Successful hypophysectomy was verified by monitoring body weights and
major urinary proteins in urine, and by post mortem inspection of the
base of the skull.
MUP Analysis--
Urine was collected from mice before and after
hypophysectomy and following hormone replacement. Samples (0.5 µl)
were run on 12% SDS-polyacrylamide gels, which were stained with
Coomassie Blue. MUP protein (major ~20-kDa protein band) was
quantified by densitometry using a Molecular Dynamics densitometer.
Samples that contained high levels of MUP were diluted as required to enable quantification.
Preparation of Mouse Liver Homogenates and Cytosolic and
Microsomal Proteins--
A total tissue homogenate was prepared by
homogenizing liver (~1 g) in 10 ml of homogenizing buffer (10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 250 mM sucrose, 1 mM sodium orthovanadate, 10 mM sodium fluoride, and 100 µM
phenylmethanesulfonyl fluoride) and centrifuging at 9,000 rpm for 15 min. Microsomal pellets were separated from the cytosolic supernatant
by ultracentrifugation (100,000 × g for 1 h),
suspended in 0.1 M KPi buffer, 0.1 mM EDTA, 20% glycerol, pH 7.4, and stored at Antibodies--
Mouse monoclonal anti-STAT1 (S21120) and
anti-STAT3 (S21320) antibodies were purchased from Transduction
Laboratories (Lexington, KY). Rabbit polyclonal anti-STAT5a (sc-1081)
and anti-STAT5b (sc-835) antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA). These STAT5 antibodies were shown to be essentially
specific for STAT5a and STAT5b, respectively, under our Western
blotting conditions (27). Rabbit polyclonal anti-rat CYP2B1 (28) and
rabbit polyclonal anti-mouse CYP2D9 antibody, obtained from Dr. M. Negishi (NIEHS, National Institutes of Health, Research Triangle Park,
NC) (29), were used for the Western blot analysis of mouse microsomal
CYP2B and CYP2D proteins, respectively.
Western Blotting--
Liver cytosolic proteins (40 µg) or
microsomal proteins (20 µg) were electrophoresed through standard
Laemmli SDS-polyacrylamide gels (10% gels for STAT proteins; 8% gels
for mouse microsomal CYP proteins), transferred to nitrocellulose
membranes and then probed with anti-STAT or anti-CYP antibodies.
Membranes were blocked for 1 h at 37 °C with 3% nonfat dry
milk and 1% BSA in a high Tween buffer (0.3% Tween 20 in
phosphate-buffered saline) for anti-STAT1 and anti-STAT3, or with 2%
Blotto and 2% BSA in TST buffer (10 mM Tris-HCl, pH 7.5, 0.1% Tween 20, 50 mM NaCl) for probing with anti-STAT5a
and anti-STAT5b. For microsomal CYP Western blotting, membranes were
blocked for 2 h at 37 °C with 3% nonfat dry milk and 1% BSA
in TST (10 mM Tris-HCl, pH 7.5, 0.1 M NaCl, and
0.1% Tween 20). Primary antibodies were diluted 1/3000 (STAT antibodies) or 1/5000 (CYP antibodies) and incubated with the membranes
for 1 h at 37 °C. Antibody binding was detected by enhanced chemiluminescence using the ECL kit from Amersham Corp. Bands visualized on x-ray film were scanned using a Cannon IX-4015 scanner and Ofoto scanning software. Nitrocellulose membranes were stripped for
20 min at 50 °C (62.5 mM Tris-HCl, pH 7.6, 2% SDS, 50 mM 2-mercaptoethanol) before reprobing.
EMSA Analysis--
Total liver homogenate protein (15 µg) was
preincubated for 10 min at room temperature with 9 µl of gel mobility
shift buffer (12.5 mM Tris-HCl, pH 7.5 containing 10 fmol
of DNA probe, 2 µg of poly(dI-dC) (Roche Molecular Biochemicals), 5%
glycerol, 1.25 mM MgCl2, 625 µM
EDTA, and 625 µM dithiothreitol). A double-stranded oligonucleotide probe containing the STAT5 response element of the rat
Pulsatile GH Replacement Stimulates Growth of Hypophysectomized
Wild-type but not hypophysectomized STAT5b-deficient
Mice--
Wild-type and STAT5b-deficient male mice were
hypophysectomized to eliminate endogenous pituitary GH. Successful
hypophysectomy was demonstrated by the cessation of body weight gain
(Fig. 1) and by the loss of MUP protein
excretion in urine (see below), and was verified by post mortem
inspection of the base of the skull and by the substantial decrease in
serum prolactin at sacrifice (data not shown). In wild-type mice,
resumption of growth, evidenced by body weight gain, was stimulated by
hormone replacement therapy in the form of pulsatile GH combined with
T4 treatment, or alternatively, pulsatile GH alone (Fig. 1,
A, closed symbols, and B).
In STAT5b-deficient mice, however, GH did not stimulate body weight
gain (Fig. 1).
MUP Excretion Is Reduced following Hypophysectomy and Restored
following GH Pulse Replacement in Wild-type but Not in STAT5b-deficient
Mice--
MUPs, which are synthesized in the liver in response to GH
and other hormonal factors (25), are excreted in urine at approximately 3-fold higher levels in male than female mice (30). MUP excretion in
wild-type male mice was markedly reduced following hypophysectomy (Fig.
2), in agreement with earlier reports in
hypophysectomized or GH-deficient mice (25, 30, 31). STAT5b-deficient
males excreted low levels of MUPs, and these were further reduced
following hypophysectomy. Pulsatile GH replacement in combination with
T4 in wild-type hypophysectomized mice increased MUP
protein excretion to the original levels of intact male mice. By
contrast, this same hormonal regimen had essentially no effect in
STAT5b-deficient mice (Fig. 2B).
Expression of STAT Proteins in the Liver Is Not Affected by
Hypophysectomy--
Western blots of liver homogenates probed with
anti-STAT antibodies confirmed the selective absence of STAT5b protein
and showed that hypophysectomy did not alter the expression of STAT1, STAT3, STAT5a, or STAT5b proteins in wild-type (Fig.
3A, lane 6 versus lanes 1 and
2) or in STAT5b-deficient mice (Fig. 3A, lane 7 versus lanes
8-10). GH pulse replacement in hypophysectomized wild-type
mice induced the appearance of a slower migrating STAT5b band (Fig.
3A, lanes 3-5), which we previously
identified as a tyrosine-phosphorylated STAT5b form (10). Similar
to our earlier observations (23), the levels of STAT1 were higher in
STAT5b-deficient compared with wild-type mice (Fig. 3A,
lanes 7-14 versus lanes 1-6), and these levels were not altered by hypophysectomy
(lane 7 versus lanes
8-10).
EMSA analysis using the STAT5-binding sequence of the rat GH Pulse Replacement Reverses Loss of Male-predominant CYP2D9 in
Hypophysectomized Wild-type Mice but Not in Hypophysectomized
STAT5b-deficient Mice--
CYP2D9 is expressed at severalfold higher
levels in males compared with females (Fig.
4A, band
b, lanes 1-3 versus
lanes 6 and 7). Moreover, livers of
STAT5b-deficient male mice express levels of CYP2D9 that are much lower
than wild-type males and are similar to those in wild-type females
(lanes 4 and 5 and lanes 6 and 7). Wild-type hypophysectomized mice also
expressed low levels of CYP2D9 (Fig. 4B, band
b, lanes 2-4), but expression was
substantially restored following GH pulse replacement (Fig. 4B, lanes 5-8). In contrast, the low
levels of CYP2D9 in hypophysectomized STAT5b-deficient male mice were
not restored by GH pulse replacement (Fig. 4C,
band b, lanes 7-9
versus lanes 2-6).
Female-specific CYP2B Enzyme Is Down-regulated by GH Pulses in
Hypophysectomized Male Wild-type but Not STAT5b-deficient
Mice--
CYP2B (band b) is expressed specifically in female mouse
liver (Fig. 5A,
lanes 6-7 versus lanes
1-3). Hypophysectomy of wild-type male mice increased CYP2B
(band b) to female levels (Fig. 5B, lanes
4-6), supporting the proposal that expression of this
protein is negatively regulated by pituitary GH (33). CYP2B (band b) is
also expressed at an elevated level in both intact and
hypophysectomized male STAT5b-deficient mice (Fig. 5, A,
lanes 4 and 5; B,
lanes 10-12). GH pulse replacement eliminated
the expression of CYP2B (band b) in wild-type males; however, there was
continued expression of this CYP following GH pulse replacement in
STAT5b-deficient males (Fig. 5B, lanes
7-9 versus lanes
13-15).
Our previous studies with STAT5b-deficient mice indicated that
STAT5b is required for multiple biological processes, and that several
of the phenotypic defects characteristic of STAT5b-deficient mice are
associated with the loss of male-specific, sexually dimorphic liver
gene expression (20, 23). However, it could not be determined from
these studies whether the observed liver phenotype reflects a direct
requirement for STAT5b for maintenance of the male liver expression
profile, or alternatively, whether the pattern of pituitary GH
secretion in STAT5b-deficient mice is altered to a more frequent secretory pattern, such as is present in females; such a change in
pituitary GH secretion would alone be sufficient to induce the
feminization of liver gene expression profiles and body growth rates
that characterizes STAT5b-deficient mice. Direct analysis of mouse
plasma GH profiles has been reported by one group (5); however, this
type of analysis presents serious technical difficulties owing to the
small blood vessels, low blood volume, difficulty in maintaining an
open catheter for blood sampling in mice, and the requirement that the
mice not be stressed during the sampling process. Moreover, in view of
the potential role of STAT5b in the established feedback effects of GH
on the hypothalamic regulation of pituitary GH secretion (34), direct
measurements of plasma GH profiles in STAT5b-deficient mice would not
provide an unambiguous answer to the question of whether the loss of
liver STAT5b per se is responsible for the observed
feminization of liver P450 profiles and body weight gain in
STAT5b-deficient mice. We therefore undertook in the present study an
alternative approach, in which the pituitary was surgically removed to
eliminate the major source of endogenous plasma GH, enabling us to
evaluate the intrinsic responsiveness of the liver to plasma GH pulses
applied exogenously.
The effects of hypophysectomy and GH pulse replacement on body growth
and liver gene expression obtained in wild-type mice were in full
agreement with earlier reports (1, 25, 35-37). First, there was no
increase in the body weights of any of the mice following
hypophysectomy. Second, GH pulse replacement, with or without
T4, stimulated a dramatic and immediate resumption of body
weight gain in wild-type mice. In contrast, hormone replacement did not
stimulate an increase in body weight in STAT5b-deficient mice. This
finding provides strong support for our proposal that there is impaired
GH signaling in STAT5b-deficient mice and that STAT5b mediates body
growth stimulated by the male pattern of pulsatile plasma GH. Further
study is required to determine the extent to which this STAT5b
dependence of body growth involves the liver acting in concert with
other tissues that mediate the whole body growth response.
Studies on the excretion of MUPs in urine provide support for the
critical importance of STAT5b in intracellular hepatocyte signaling.
MUPs are a family proteins of ~20 kDa that are expressed in and
secreted by the liver. There are 35-40 MUP genes and pseudogenes in
mice (38, 39), and the encoded MUP proteins are thought to contribute
to scent marking of territories (40). About 3-fold higher levels of
MUPs are excreted in male compared with female mouse urine, and the
high level expression of some of these genes is induced by pulsatile GH
and suppressed by GH administered continuously. The expression of other
MUP genes is induced to a smaller degree by pulsatile GH (30, 31, 41).
We previously reported that STAT5b-deficient male mice have MUP levels
that are lower than wild-type male mice and are similar to those in
wild-type female mice (23). However, the MUP levels in urine of female
STAT5b-deficient mice were lower than in the corresponding female
wild-type control mice in that study, suggesting that STAT5b might also
be generally involved in intracellular GH signaling, and not solely in
signaling in response to GH pulses. Because T4 is also
required for the expression of MUP proteins (25), T4 was
added to the drinking water when we evaluated the responsiveness of
urinary MUP levels to GH pulse replacement. Pulsatile GH in combination
with T4 replacement stimulated restoration of urinary MUP
levels in wild-type but not in STAT5b-deficient mice (Fig. 2), in
support of a role for STAT5b in mediating hepatic responses to
pulsatile GH at the level of MUP gene expression.
The third observation implicating STAT5b in pulsatile GH signaling
pathways comes from cytochrome P450 gene expression studies. We showed
previously that the selective loss of male-specific liver cytochrome
P450 gene expression in STAT5b-deficient males is coupled with
expression of cytochrome P450 genes that are normally expressed only in
females (20, 23). Removal of the pituitary gland followed by pulsatile
GH stimulation of the liver was presently shown to restore expression
of the male-specific liver enzyme CYP2D9 while suppressing the
expression of a female-specific CYP2B enzyme in wild-type, but not
STAT5b-deficient hypophysectomized male mice (Figs. 4 and 5).
Presumably, STAT5b acts in a positive manner to stimulate expression of
CYP2D9 and other male-expressed liver CYPs by
trans-activating STAT5 response elements found in the
5'-flanking DNA of this group of genes
(21).2 The mechanism
responsible for the apparent negative regulation by STAT5b of certain
female-expressed liver CYPs (e.g. CYP2B, band b; Fig. 5 and
Ref. 20) is uncertain, but could involve "negative STAT5 response
elements" or perhaps other, more complex mechanisms. Further studies
will be required to elucidate the detailed molecular mechanisms through
which STAT5b mediates the sexually dimorphic regulation of liver CYP expression.
Although GH pulse treatment did not restore the normal male pattern of
body weight gain and MUP and CYP gene expression in STAT5b-deficient
mice, it did activate STAT5a in livers of these animals, as
demonstrated by EMSA analysis (Fig. 3B). Accordingly, GH
receptor, JAK2 tyrosine kinase, and other cellular factors required for
GH pulsed-induced liver STAT activation are present and functional in
the livers of STAT5b-deficient mice. This finding provides further
support for our proposal that it is the deficiency in STAT5b per
se that gives rise to the observed GH pulse-resistance phenotype
of these animals. STAT5a, when activated by GH pulses in livers of
these mice, may either be intrinsically ineffective with respect to
stimulating and maintaining a male pattern of liver gene expression, or
perhaps may be present at a level that is too low (20) to effectively
carry out these STAT5b-stimulated responses. STAT5a does, however,
contribute to the expression of certain female-expressed CYPs, perhaps
via a mechanism that involves heterodimerization with STAT5b (20).
The present study establishes that STAT5b-deficient mice exhibit a GH
pulse resistance phenotype that leads to the observed major alterations
in sex-dependent liver CYP gene expression and pubertal body growth rates. However, this finding does not rule out the
possibility that STAT5b may additionally help regulate the hypothalamic
control of pituitary GH secretion (42), and that the pattern of
pituitary GH secretion may consequently be altered in STAT5b-deficient
mice. Indeed, we have reported increases in plasma GH levels in
STAT5b-deficient mice at sacrifice (23). Moreover, decreased
somatostatin mRNA in hypothalamic periventricular nuclei has been
observed in STAT5b-deficient mice, providing indirect evidence that
pituitary GH secretion may be increased in these animals (43). Further
study will be required to elucidate the role of STAT5b in these and
other physiologically important hormonal regulatory circuits.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-casein in the mammary gland (11, 12), mammary
gland factor was renamed STAT5 when the cDNA was cloned and shown
to be a member of the STAT family of transcription factors (13).
Subsequently, two separate genes were identified and shown to be
expressed in a wide range of tissues (14-17). STAT5a and STAT5b are
now known to be differentially expressed in various tissues, and to
have independent and distinct as well as common functions (18-20).
STAT5b accounts for ~90% of the STAT5 in the liver; however, STAT5b
and STAT5a are both required for the constitutive expression of certain
GH-regulated liver cytochrome P450 enzymes (20).
-deficient mice (22),
and from our analysis of STAT5b-deficient mice, which displayed loss of
male-specific pubertal body growth and male-specific liver gene
expression (23). However, it is unclear from these studies whether GH
target tissues such as liver become unresponsive to pulsatile GH as a
direct consequence of the loss of STAT5b, or whether an alteration in the pattern of pituitary GH secretion in these animals leads to the
observed phenotypes.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
80 °C until use.
Animal procedures were approved by the Ruakura Animal Ethics Committee
operating under the guidelines of the New Zealand National Animal
Ethics Advisory Committee.
80 °C
until use. Cytosolic and total tissue homogenate protein concentrations
were determined using the Bio-Rad DC detergent protein assay kit with
bovine serum albumin as a standard. Microsomal protein concentrations
were determined using the Bradford assay kit (Sigma).
-casein promoter (nucleotides
101 to
80,
5'-GGA-CTT-CTT-GGA-ATT-AAG-GGA-3') was end-labeled on one strand with
32P using T4 kinase. The probe was incubated for 20 min at
room temperature and 10 min on ice, to stabilize the STAT5-DNA
gel-shift complex (9), then added to the protein-buffer mix. For
supershift analysis, an additional 10-min incubation in the presence of
STAT antibodies was carried out after the addition of the labeled DNA probe. Antibodies used were anti-STAT5a (sc-1081x) and anti-STAT5b (sc-835) from Santa-Cruz. Following 30 min of pre-electrophoresis, the
samples were electrophoresed through non-denaturing polyacrylamide gels
(5.5% acrylamide, 0.07% bisacrylamide) (National Diagnostics, Atlanta, GA) in 0.5× TBE (44.5 mM Trizma base, 44.5 mM boric acid, 5 mM EDTA) for 20 min in the
cold room at 120 V, then at room temperature. DNA-protein complexes
were visualized by PhosphorImager analysis.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (27K):
[in a new window]
Fig. 1.
Effect of GH pulses on body weight gain in
hypophysectomized male wild-type and STAT5b-deficient mice.
A, shown are body weights of representative individual
wild-type (solid symbols) and STAT5b-deficient
(open symbols) male mice following
hypophysectomy, and during two separate 7-day periods of hormone
replacement (pulsatile GH + T4 from days 37-44 and
pulsatile GH alone from days 63-70). Day 0 corresponds to ~3 weeks
after hypophysectomy. B, changes in body weights during a
7-day period when hypophysectomized male mice were either untreated or
were treated twice daily with pulses of GH pulses as described under
"Experimental Procedures" (days 0-7). The averages and maximum
standard errors of the differences between the means (sed),
are shown for GH-treated wild-type (
; n = 10),
untreated wild-type (
; n = 7), GH-treated
STAT5b-deficient (
; n = 9), and untreated
STAT5b-deficient (
; n = 6) male mice.

View larger version (34K):
[in a new window]
Fig. 2.
Pulsatile GH combined with thyroxine
treatment restore MUP expression in hypophysectomized male wild-type
mice but not in STAT5b-deficient mice. A, MUP proteins
(~20 kDa) excreted in urine obtained from individual mice were
analyzed on 12% SDS gels. Shown are gels of representative urine
samples after staining with Coomassie Blue. B, relative
amounts of MUP proteins in wild-type (n = 3) and
STAT5b-deficient mice (n = 4) were quantified using
densitometry. Bars indicate standard errors of the means.
Urinary samples from wild-type and STAT5b-deficient mice were collected
prior to hypophysectomy (Pre-Hx), after hypophysectomy
(Hx), and following 7 days of hormone replacement (GH + T4).

View larger version (68K):
[in a new window]
Fig. 3.
Expression of STAT proteins
(A) and STAT5 EMSA activity (B) in
hypophysectomized wild-type and STAT5b-deficient male mice.
A, total liver homogenates (40 µg) were analyzed on
Western blots probed sequentially with the indicated anti-STAT
antibodies. The livers were from hypophysectomized (Hx) or
intact control (
) wild-type and STAT5b-deficient mice.
Hypophysectomized mice were untreated (
GH) or were
treated with pulsatile GH replacement for 7 days (+ GH).
STAT1
(upper band of doublet) corresponds to the DNA-binding active
form of STAT1. STAT5b doublet seen in lanes 3-5
is comprised of non-phosphorylated (lower band) and
tyrosine-phosphorylated (upper band) STAT5b forms. The corresponding
non-phosphorylated and tyrosine-phosphorylated forms of the other STATs
do not resolve well on these gels. B, EMSA of total liver
homogenates using the STAT5 binding site from the rat
-casein
promoter as a probe. Anti-STAT5a (5a) and STAT5b
(5b) antibodies were used to supershift EMSA complexes
containing STAT5a (lanes 7 and 14) or
STAT5b (lanes 8 and 15). The
STAT5/
-casein DNA complexes and the supershifted bands are marked
with arrows. Some immune cross-reactivity between STAT5b
antibodies and STAT5a present in the STAT5b-deficient liver samples is
evident (lane 15) (see "Results").
-casein
promoter (32) showed that there was negligible STAT5 DNA binding
activity in liver extracts from both wild-type and STAT5b-deficient
hypophysectomized mice (Fig. 3B, lanes
1-3 and 9-11). This finding is in accord with
the requirement of pituitary GH for STAT5 tyrosine phosphorylation and
DNA binding activity indicated by studies carried out in the rat liver
model (8). GH replacement strongly increased DNA binding in
hypophysectomized wild-type mice (Fig. 3B, lanes
4-6). A significant, albeit weaker STAT5 EMSA activity was
obtained in hypophysectomized STAT5b-deficient mice after GH pulse
treatment (Fig. 3B, lanes 12 and
13). In wild-type mice these EMSA bands were partially
supershifted by anti-STAT5a antibodies (Fig. 3B,
lane 7) and completely supershifted by
anti-STAT5b antibodies (Fig. 3B, lane
8). These supershifted bands primarily contain STAT5b
homodimers, but also include STAT5a homodimers and STAT5a-STAT5b
heterodimers (20). The weak STAT5-DNA complex formed by liver extracts
from STAT5b-deficient mice given GH pulse replacement was completely
supershifted by anti-STAT5a antibody (Fig. 3B,
lane 14), consistent with the complex
corresponding to a STAT5a-STAT5a homodimer that is formed in livers
deficient in STAT5b. The supershift with anti-STAT5b antibodies seen in STAT5b-deficient liver extracts (Fig. 3B, lane
15) is indicative of cross-reactivity between this antibody
and STAT5a under conditions of EMSA analysis, as discussed elsewhere
(27).

View larger version (45K):
[in a new window]
Fig. 4.
Effect of hypophysectomy and pulsatile GH
replacement on CYP2D9 gene expression in wild-type and STAT5b-deficent
mice. A, liver microsomal proteins from individual male
and female, wild-type (WT) and STAT5b-deficient
(KO, knockout) mice were analyzed by Western blotting for
the expression of CYP2D9 (Band b). CYP2D9 is
expressed predominantly in males. Panels B and
C, Western blot analysis, using anti-CYP2D9 antibodies, of
liver microsomes prepared from individual hypophysectomized
(Hx) wild-type and STAT5b-deficient male mice that were
untreated (
GH) or were given pulsatile GH replacement
treatment (+ GH), as indicated.

View larger version (29K):
[in a new window]
Fig. 5.
Effect of hypophysectomy and pulsatile GH
replacement on CYP2B gene expression in wild-type and STAT5b-deficent
mice. A, Western blot analysis of liver microsomal
proteins from male and female wild-type (WT) and
STAT5b-deficient (KO) mice probed with anti-CYP2B
antibodies. CYP2B band b is expressed predominantly in
female mice. B, Western blot analysis of male
hypophysectomized (Hx) wild-type and STAT5b-deficient mice
(KO) that were untreated (
GH) or given
pulsatile GH replacement (+GH), as indicated.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. M. Negishi for provision of CYP2D9 antibody, Ric Broadhurst for assistance with anesthesia and surgery, Glenda Smith and Bobby Smith for assisting with care of the mice, and Harold Henderson for statistical advice.
| |
FOOTNOTES |
|---|
* This work was supported by a grant from the New Zealand Foundation for Research, Science and Technology (to H. W. D.) and by National Institutes of Health Grant DK33765 (to D. J. W.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ These authors contributed equally to this work.
¶ To whom correspondence may be addressed. Fax: 64-7-838-5628; E-mail: daveyh@agresearch.cri.nz.

To whom correspondence may be addressed. Fax: 617-353-7404;
E-mail: djw@bio.bu.edu.
2 S.-H. Park and D. J. Waxman, unpublished results.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: GH, growth hormone; STAT, signal transducer and activator of transcription; MUP, major urinary proteins, EMSA, electrophoretic mobility shift assay; CYP, cytochrome P450; T4, thyroxine; BSA, bovine serum albumin; JAK2, Janus tyrosine kinase 2.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Isaksson, O. G. P., Eden, S., and Jansson, J.-O. (1985) Annu. Rev. Physiol. 47, 483-499[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Jansson, J.-O., Ekberg, S., and Isaksson, O. (1985) Endocr. Rev. 6, 128-150[Abstract] |
| 3. | Shapiro, B. H., Agrawal, A. K., and Pampori, N. A. (1995) Int. J. Biochem. Cell Biol. 27, 9-20[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Waxman, D. J., and Chang, T. K. H. (1995) in Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., ed), 2nd Ed. , pp. 391-417, Plenum Press, New York |
| 5. | MacLeod, J. N., Pampori, N. A., and Shapiro, B. H. (1991) J. Endocrinol. 131, 395-399[Abstract] |
| 6. | Carter-Su, C., and Smit, L. S. (1998) Rec. Prog. Horm. Res. 53, 61-82 |
| 7. | Davey, H. W., Wilkins, R. J., and Waxman, D. J. (1999) Am. J. Hum. Genet. 65, 959-965[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Waxman, D. J.,
Ram, P. A.,
Park, S.-H.,
and Choi, H. K.
(1995)
J. Biol. Chem.
270,
13262-13270 |
| 9. |
Gebert, C. A.,
Park, S. H.,
and Waxman, D. J.
(1997)
Mol. Endocrinol.
11,
400-414 |
| 10. |
Ram, P. A.,
Park, S.-H.,
Choi, H. K.,
and Waxman, D. J.
(1996)
J. Biol. Chem.
271,
5929-5940 |
| 11. |
Wakao, H.,
Schmitt-Ney, N. M.,
and Groner, B.
(1992)
J. Biol. Chem.
267,
16365-16370 |
| 12. | Schmitt-Ney, M., Happ, B., Hofer, P., Hynes, N. E., and Groner, B. (1992) Mol. Endocrinol. 6, 1988-1997[Abstract] |
| 13. | Wakao, H., Gouilleux, F., and Groner, B. (1994) EMBO J. 13, 2182-2191[Medline] [Order article via Infotrieve] |
| 14. |
Lin, J.-X.,
Mietz, J.,
Modi, W. S.,
John, S.,
and Leonard, W. J.
(1996)
J. Biol. Chem.
271,
10738-10744 |
| 15. |
Liu, X.,
Robinson, G. W.,
Gouilleux, F.,
Groner, B.,
and Hennighausen, L.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8831-8835 |
| 16. | Azam, M., Erdjument-Bromage, H., Kreider, B. L., Xia, M., Quelle, F., Basu, R., Saris, C., Tempst, P., Ihle, J. N., and Schindler, C. (1995) EMBO J. 14, 1402-1411[Medline] [Order article via Infotrieve] |
| 17. | Mui, A. L.-F., Wakao, H., O'Farrell, A.-M., Harada, N., and Miyajima, A. (1995) EMBO J. 14, 1166-1175[Medline] [Order article via Infotrieve] |
| 18. |
Verdier, F.,
Rabionet, R.,
Gouilleux, F.,
Beisenherzhuss, C.,
Varlet, P.,
Muller, O.,
Mayeux, P.,
Lacombe, C.,
Gisselbrecht, S.,
and Chretien, S.
(1998)
Mol. Cell. Biol.
18,
5852-5860 |
| 19. |
Yamashita, H.,
Xu, J.,
Erwin, R. A.,
Farrar, W. L.,
Kirken, R. A.,
and Rui, H.
(1998)
J. Biol. Chem.
273,
30218-30224 |
| 20. |
Park, S. H.,
Liu, X.,
Hennighausen, L.,
Davey, H. W.,
and Waxman, D. J.
(1999)
J. Biol. Chem.
274,
7421-7430 |
| 21. |
Subramanian, A.,
Wang, J. M.,
and Gil, G.
(1998)
Nucleic Acids Res.
26,
2173-2178 |
| 22. |
Sueyoshi, T.,
Yokomori, N.,
Korach, K. S.,
and Negishi, M.
(1999)
Mol. Pharmacol.
56,
473-477 |
| 23. |
Udy, G. B.,
Towers, R. P.,
Snell, R. G.,
Wilkins, R. J.,
Park, S. H.,
Ram, P. A.,
Waxman, D. J.,
and Davey, H. W.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
7239-7244 |
| 24. |
Noshiro, M.,
and Negishi, M.
(1986)
J. Biol. Chem.
261,
15923-1592723 |
| 25. | Knopf, J. L., Gallagher, J. F., and Held, W. A. (1983) Mol. Cell. Biol. 3, 2234-2240 |
| 26. | Averill, R. L. W., Grattan, D. R., and Norris, S. K. (1991) Endocrinology 128, 705-709[Abstract] |
| 27. |
Choi, H. K.,
and Waxman, D. J.
(1999)
Endocrinology
140,
5126-5135 |
| 28. |
Waxman, D. J.,
and Walsh, C.
(1982)
J. Biol. Chem.
257,
10446-57 |
| 29. |
Harada, N.,
and Negishi, M.
(1984)
J. Biol. Chem.
259,
12285-90 |
| 30. | Norstedt, G., and Palmiter, R. (1984) Cell 36, 805-812[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | Johnson, D., al-Shawi, R., and Bishop, J. O. (1995) Mol. Endocrinol. 14, 21-34 |
| 32. |
Schmitt-Ney, M.,
Happ, B.,
Mall, R. K.,
and Groner, B.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
3130-3134 |
| 33. | Sharma, M. C., Agrawal, A. K., Sharma, M. R., and Shapiro, B. H. (1998) Biochem. Pharmacol. 56, 1251-8[CrossRef][Medline] [Order article via Infotrieve] |
| 34. | Minami, S., Kamegai, J., Sugihara, H., Suzuki, N., and Wakabayashi, I. (1998) Endocr. J 45 suppl., S19-S26 |
| 35. | Lynch, K. R., Dolan, K. P., Nakhasi, H. L., Unterman, R., and Feigelson, P. (1982) Cell 28, 185-189[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Pampori, N. A., Agrawal, A. K., and Shapiro, B. H. (1991) Acta Endocrinol. 124, 283-289 |
| 37. |
Waxman, D. J.,
Pampori, N. A.,
Ram, P. A.,
Agrawal, A. K.,
and Shapiro, B. H.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
6868-6872 |
| 38. | Bishop, J. O., Clarke, A. J., Clissold, P. M., Hainey, S., and Francke, U. (1982) EMBO J. 1, 615-620[Medline] [Order article via Infotrieve] |
| 39. |
Bennett, K. L.,
Lalley, P. A.,
Barth, R. K.,
and Hastia, N. D.
(1982)
Proc. Natl. Acad. Sci. U. S. A.
79,
1220-1224 |
| 40. | Hurst, J. L., Robertson, D. H. L., Tolladay, U., and Beynon, R. J. (1998) Anim. Behav. 55, 1289-1297[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Johnson, D., Harrison, S., Pineda, N., Heinlein, C., al-Shawi, R., and Bishop, J. O. (1995) J. Mol. Endocrinol. 14, 35-49[Abstract] |
| 42. | Bluet-Pajot, M. T., Epelbaum, J., Gourdji, D., Hammond, C., and Kordon, C. (1998) Cell. Mol. Neurobiol. 18, 101-123[CrossRef][Medline] [Order article via Infotrieve] |
| 43. | Luckman, S. M., McGuiness, L., Thomas, G. B., Robinson, I. C. A. F., Udy, G. B., and Davey, H. W. (1998) Annual Meeting of the Society for Neuroscience, November 7-12, Los Angeles, CA, Abstract |
This article has been cited by other articles:
![]() |
S. Eleswarapu, Z. Gu, and H. Jiang Growth Hormone Regulation of Insulin-Like Growth Factor-I Gene Expression May Be Mediated by Multiple Distal Signal Transducer and Activator of Transcription 5 Binding Sites Endocrinology, May 1, 2008; 149(5): 2230 - 2240. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Holloway, Y. Cui, E. V. Laz, A. Hosui, L. Hennighausen, and D. J. Waxman Loss of Sexually Dimorphic Liver Gene Expression upon Hepatocyte-Specific Deletion of Stat5a-Stat5b Locus Endocrinology, May 1, 2007; 148(5): 1977 - 1986. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Han, B. Osuntokun, N. Benight, K. Loesch, S. J. Frank, and L. A. Denson Signal Transducer and Activator of Transcription 5b Promotes Mucosal Tolerance in Pediatric Crohn's Disease and Murine Colitis Am. J. Pathol., December 1, 2006; 169(6): 1999 - 2013. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Waxman and C. O'Connor Growth Hormone Regulation of Sex-Dependent Liver Gene Expression Mol. Endocrinol., November 1, 2006; 20(11): 2613 - 2629. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lee, J. R. Hutson, V. K.-F. Tzau, and D. S. Riddick Regulation of Constitutive Mouse Hepatic Cytochromes P450 and Growth Hormone Signaling Components by 3-Methylcholanthrene Drug Metab. Dispos., September 1, 2006; 34(9): 1530 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu, Z. Liu, T. L. Clemens, and J. L. Messina Insulin Reverses Growth Hormone-induced Homologous Desensitization J. Biol. Chem., August 4, 2006; 281(31): 21594 - 21606. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. H. Clodfelter, M. G. Holloway, P. Hodor, S.-H. Park, W. J. Ray, and D. J. Waxman Sex-Dependent Liver Gene Expression Is Extensive and Largely Dependent upon Signal Transducer and Activator of Transcription 5b (STAT5b): STAT5b-Dependent Activation of Male Genes and Repression of Female Genes Revealed by Microarray Analysis Mol. Endocrinol., June 1, 2006; 20(6): 1333 - 1351. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Vesper, L. T. Raetzman, and S. A. Camper Role of Prophet of Pit1 (PROP1) in Gonadotrope Differentiation and Puberty Endocrinology, April 1, 2006; 147(4): 1654 - 1663. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Holloway, E. V. Laz, and D. J. Waxman Codependence of Growth Hormone-Responsive, Sexually Dimorphic Hepatic Gene Expression on Signal Transducer and Activator of Transcription 5b and Hepatic Nuclear Factor 4{alpha} Mol. Endocrinol., March 1, 2006; 20(3): 647 - 660. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Held, W. Cosme-Blanco, L. M. Difedele, E. L. Bonkowski, R. K. Menon, and L. A. Denson Alterations in growth hormone receptor abundance regulate growth hormone signaling in murine obstructive cholestasis Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G986 - G993. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kotokorpi, C. Gardmo, C. S. Nystrom, and A. Mode Activation of the Glucocorticoid Receptor or Liver X Receptors Interferes with Growth Hormone-Induced akr1b7 Gene Expression in Rat Hepatocytes Endocrinology, December 1, 2004; 145(12): 5704 - 5713. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Wiwi, M. Gupte, and D. J. Waxman Sexually Dimorphic P450 Gene Expression in Liver-Specific Hepatocyte Nuclear Factor 4{alpha}-Deficient Mice Mol. Endocrinol., August 1, 2004; 18(8): 1975 - 1987. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Tronche, C. Opherk, R. Moriggl, C. Kellendonk, A. Reimann, L. Schwake, H. M. Reichardt, K. Stangl, D. Gau, A. Hoeflich, et al. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth Genes & Dev., March 1, 2004; 18(5): 492 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Badger, M. J. J. Ronis, S. J. Frank, Y. Chen, and L. He Effects of Chronic Ethanol on Hepatic and Renal CYP2C11 in the Male Rat: Interactions with the Janus-Kinase 2-Signal Transducer and Activators of Transcription Proteins 5b Pathway Endocrinology, September 1, 2003; 144(9): 3969 - 3976. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Denson, M. A. Held, R. K. Menon, S. J. Frank, A. F. Parlow, and D. L. Arnold Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3 Am J Physiol Gastrointest Liver Physiol, April 1, 2003; 284(4): G646 - G654. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Liu, L. Robillard, B. Banihashemi, and P. R. Albert Growth Hormone-induced Diacylglycerol and Ceramide Formation via Galpha i3 and Gbeta gamma in GH4 Pituitary Cells. POTENTIATION BY DOPAMINE-D2 RECEPTOR ACTIVATION J. Biol. Chem., December 6, 2002; 277(50): 48427 - 48433. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Jaffe, D. K. Turgeon, K. Lown, R. Demott-Friberg, and P. B. Watkins Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E1008 - E1015. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. R. Simon, J. Fortune, M. Iwahashi, and E. Sutherland Sexual dimorphic expression of ADH in rat liver: importance of the hypothalamic-pituitary-liver axis Am J Physiol Gastrointest Liver Physiol, September 1, 2002; 283(3): G646 - G655. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Pass, W. Becker, R. Kluge, K. Linnartz, L. |